Author:
Khan Mohammad Afsar,Singh Deepti,Jameel Mohd.,Maurya Santosh K.,Singh Swati,Akhtar Kafil,Siddique Hifzur R.
Funder
Department of Science and Technology, Ministry of Science and Technology, India
University Grants Commission
Science and Engineering Research Board
Reference27 articles.
1. ARCHES: a randomized, phase III study of androgen deprivation therapy with enzalutamide or placebo in men with metastatic hormone-sensitive prostate cancer;Armstrong;J. Clin. Oncol.,2019
2. Epigenetic modifications of c-MYC: role in cancer cell reprogramming, progression and chemoresistance;Fatma;Semin. Cancer Biol.,2022
3. Androgen receptor signaling in the development of castration-resistant prostate cancer;Feng;Front. Oncol.,2019
4. Enzalutamide, an androgen receptor signaling inhibitor, induces tumor regression in a mouse model of castration-resistant prostate cancer;Guerrero;Prostate.,2013
5. Antiandrogen enzalutamide induced genetic, cellular, and hepatic damages: amelioration by triterpene Lupeol;Khan;Drug Chem. Toxicol.,2023
Cited by
3 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献